Melbourne + 61.3.9101.6875

Arden Yeh joined our New Lawyers Group (NLG) in 2023. The NLG provides our newest lawyers with the opportunity to gain exposure to different practice areas and lawyering styles before making a commitment to a specific practice. Individuals in the NLG may focus on a particular area of practice, or compare practices, during their first year with Jones Day. Arden has special interests in intellectual property, the regulation of emerging technologies, data privacy, and environmental law.

Prior to joining the Firm, Arden has worked as a scientific researcher in the field of cancer genetics. She has helped elucidate the process of regeneration and transdetermination in Drosophila by mapping the mutations that are responsible for an increased frequency of transdetermination. She also contributed to the existing scholarship in the role of gastrokines in attenuating acute gastric lesions.

Arden also served at the Victorian Bar while attending law school where she assisted preeminent Senior and King's Counsel on complex litigation at the Victorian Supreme Court and at the Australian High Court. During this time she worked on matters that included challenging the constitutional validity of the COVID-19 Mandatory Vaccination (Workers) Directions and the abolition of the peak indebtedness rule in the context of liquidation and insolvency.


  • Corpay acquires GPS Capital MarketsJones Day advised Corpay, Inc. in the acquisition of GPS Capital Markets, LLC and its subsidiaries, a group that provides business-to-business cross-border and treasury management solutions, in Corpay’s third largest deal ever.
  • Consilio acquires Lawyers on Demand and SYKEJones Day advised Consilio, Inc. in the acquisition of Lawyers On Demand (LOD), a provider of legal resourcing and SYKE, a legal technology consultancy from Bowmark Capital.
  • Sanofi challenges Amgen's patent applications for anti-PCSK9 antibodies before Australian Patent OfficeJones Day is acting in an opposition proceeding for Sanofi and Regeneron in relation to their challenge to a portfolio of applications held by Amgen Inc. that claim anti-PCSK9 antibodies and their use in the treatment of hypercholesterolemia.
  • ToolGen defends revolutionary CRISPR technology patentJones Day is acting for ToolGen, Inc. in relation to a challenge to its patent rights concerning CRISPR, a technology that has revolutionized the field of molecular biology including gene editing in the medical, biotechnology, and agricultural and farming industries.
  • Additional Publications

    • 2024
      Ministerial Negligence: Realising Its Fleeting Utility in Environmental Law through the Environment Protection and Biodiversity Act 1999 (Cth) (2024) 40(4) Environment and Planning Law Journal (forthcoming)
    • 2023
      Towards Greater Cultural Diversity in Law: A Systemic Bifurcated Legal and Policy Approach (Winning Paper of the 2023 William Ah Ket Scholarship)